Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C

被引:81
作者
Harrison, SA
Brunt, EM
Qazi, RA
Oliveri, DA
Neuschwander-Tetri, BA
Di Bisceglie, AM
Bacon, BR
机构
[1] Brooke Army Med Ctr, Dept Med, Div Gastroenterol & Hepatol, Ft Sam Houston, TX 78234 USA
[2] St Louis Univ, St Louis Univ Liver Ctr, St Louis, MO 63103 USA
[3] St Louis Univ, Dept Internal Med, St Louis, MO 63103 USA
[4] St Louis Univ, Dept Pathol, St Louis, MO 63103 USA
关键词
D O I
10.1016/S1542-3565(05)00246-6
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Treatment of chronic hepatitis C (CHC) results in an average sustained viral response (SVR) rate of 54%-63%. Most previous studies have not separately reported SVR rates for patients who have CHC and concomitant significant hepatic steatosis (>33%) or histologic evidence of steatohepatitis (SH). The aim of this study was to evaluate SVR in patients with CHC plus steatosis or SH on biopsy examination, compared with a group of controls with CHC and no significant steatosis or SH. Methods: Our surgical pathology database and clinical files were queried for CHC between 1997 to 2002. Biopsy specimens with both CHC and significant steatosis (>33%) or SH were categorized as group :1. Of the patients treated with antiviral therapy, information on either SVR (hepatitis C virus [HCV] RNA negative at 6 months posttreatment) or lack of SVR (nonresponse as early as 12 weeks into therapy and relapsers) with either interferon (IFN)/ribavirin or pegylated IFN/ribavirin was found in 84 patients. A control group (group 2) of 231 CHC patients was identified by using a 2-year database (January 2000 -June 200:1) of patients without evidence of greater than 33% steatosis or SH. Results: The overall SVR was 28% in group 1, compared with 44% for group 2 (P =.001). For HCV genotype 1, the SVR was 23% vs 34% for group 2 (P =.19). For HCV genotypes 2 and 3, the SVR was 42% vs 78% for groups 1 and 2 (P =.008), respectively. Conclusions: Overall SVR for patients with HCV and significant steatosis or SH is considerably lower than for HCV and steatosis less than 33% and no SH.
引用
收藏
页码:604 / 609
页数:6
相关论文
共 31 条
[1]   Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity [J].
Adinolfi, LE ;
Gambardella, M ;
Andreana, A ;
Tripodi, MF ;
Utili, R ;
Ruggiero, G .
HEPATOLOGY, 2001, 33 (06) :1358-1364
[2]   THE HISTOLOGICAL FEATURES OF CHRONIC HEPATITIS-C AND AUTOIMMUNE CHRONIC HEPATITIS - A COMPARATIVE-ANALYSIS [J].
BACH, N ;
THUNG, SN ;
SCHAFFNER, F .
HEPATOLOGY, 1992, 15 (04) :572-577
[3]   Projection of diabetes burden through 2050 - Impact of changing demography and disease prevalence in the US [J].
Boyle, JP ;
Honeycutt, AA ;
Narayan, KMV ;
Hoerger, TJ ;
Geiss, LS ;
Chen, H ;
Thompson, TJ .
DIABETES CARE, 2001, 24 (11) :1936-1940
[4]   High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C [J].
Bressler, BL ;
Guindi, M ;
Tomlinson, G ;
Heathcote, J .
HEPATOLOGY, 2003, 38 (03) :639-644
[5]   Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions [J].
Brunt, EM ;
Janney, CG ;
Di Bisceglie, AM ;
Neuschwander-Tetri, BA ;
Bacon, BR .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (09) :2467-2474
[6]   Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease [J].
Brunt, EM ;
Ramrakhiani, S ;
Cordes, BG ;
Neuschwander-Tetri, BA ;
Janney, CG ;
Bacon, BR ;
Di Bisceglie, AM .
MODERN PATHOLOGY, 2003, 16 (01) :49-56
[7]   Host- and disease-specific factors affecting steatosis in chronic hepatitis C [J].
Czaja, AJ ;
Carpenter, HA ;
Santrach, PJ ;
Moore, SB .
JOURNAL OF HEPATOLOGY, 1998, 29 (02) :198-206
[8]   Prevalence and trends in obesity among US adults, 1999-2000 [J].
Flegal, KM ;
Carroll, MD ;
Ogden, CL ;
Johnson, CL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (14) :1723-1727
[9]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[10]   HISTOPATHOLOGY OF HEPATITIS-C VIRUS-INFECTION [J].
GOODMAN, ZD ;
ISHAK, KG .
SEMINARS IN LIVER DISEASE, 1995, 15 (01) :70-81